Monday - November 3, 2025
Published in The Lancet: Nipocalimab Significantly Decreased Sjogren's Disease (SjD) Activity and Severity Through Substantial Reduction in Sjogren's-related Autoantibodies
October 25, 2025
RARITAN, New Jersey, Oct. 25 (TNSjou) -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release on Oct. 24, 2025:

* * *

Published in The Lancet: Nipocalimab significantly decreased Sjogren's disease (SjD) activity and severity through substantial reduction in Sjogren's-related autoantibodies

Nipocalimab, a first-in-class FcRn blocker being investigated for Sj . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products